Across TCGA pan-cancer cohorts, RNA5SP299 RNA differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of RNA5SP299’s most consistent transcriptional readouts.
The strongest signal is observed in breast invasive carcinoma (BRCA), where RNA5SP299 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RNA5SP299 is over-expressed in tumor.
BRCA and LUSC are the cancer types where RNA5SP299 tumor–normal differential expression is most reproducible.